|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
3
|
Spiro SG and Silvestri GA: One hundred
years of lung cancer. Am J Resp Crit Care Med. 17:2523–2529.
2005.
|
|
4
|
Harmsma M, Schutte B and Ramaekers FC:
Serum markers in small cell lung cancer: Opportunities for
improvement. Biochim Biophys Acta. 1836:255–272. 2013.PubMed/NCBI
|
|
5
|
Fernandez S, Risolino M, Mandia N, Talotta
F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P:
miR-340 inhibits tumor cell proliferation and induces apoptosis by
targeting multiple negative regulators of p27 in non-small cell
lung cancer. Oncogene. 34:3240–3250. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu J, Cheng Y, Li Y, Jin Z, Pan Y, Liu G,
Fu S, Zhang Y, Feng K and Feng Y: microRNA-128 plays a critical
role in human non-small cell lung cancer tumourigenesis,
angiogenesis and lymphangiogenesis by directly targeting vascular
endothelial growth factor-C. Eur J Cancer. 50:2336–2350. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fiori ME, Barbini C, Haas TL, Marroncelli
N, Patrizii M, Biffoni M and De Maria R: Antitumor effect of
miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ.
21:774–782. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harfe BD: MicroRNAs in vertebrate
development. Curr Opin Genet Dev. 15:410–415. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He HC, Han ZD, Dai QS, Ling XH, Fu X, Lin
ZY, Deng YH, Qin GQ, Cai C, Chen JH, et al: Global analysis of the
differentially expressed miRNAs of prostate cancer in Chinese
patients. BMC Genomics. 14:7572013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
White NM, Khella HW, Grigull J, Adzovic S,
Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA,
et al: miRNA profiling in metastatic renal cell carcinoma reveals a
tumour-suppressor effect for miR-215. Br J Cancer. 105:1741–1749.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen L, Li Y, Fu Y, Peng J, Mo MH,
Stamatakos M, Teal CB, Brem RF, Stojadinovic A, Grinkemeyer M, et
al: Role of deregulated microRNAs in breast cancer progression
using FFPE tissue. PLoS One. 8:e542132013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sallustio F, Serino G, Costantino V, Curci
C, Cox SN, De Palma G and Schena FP: miR-1915 and miR-1225-5p
regulate the expression of CD133, PAX2 and TLR2 in adult renal
progenitor cells. PLoS One. 8:e682962013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakazawa K, Dashzeveg N and Yoshida K:
Tumor suppressor p53 induces miR-1915 processing to inhibit Bcl-2
in the apoptotic response to DNA damage. FEBS J. 281:2937–2944.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu K, Liang X, Cui D, Wu Y, Shi W and Liu
J: miR-1915 inhibits Bcl-2 to modulate multidrug resistance by
increasing drug-sensitivity in human colorectal carcinoma cells.
Mol Carcinog. 52:70–78. 2013. View
Article : Google Scholar
|
|
17
|
Yekta S, Shih IH and Bartel DP:
MicroRNA-directed cleavage of HOXB8 mRNA. Science. 304:594–596.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dong Y, Xiong M, Duan L, Liu Z, Niu T, Luo
Y, Wu X, Xu C and Lu C: H2AX phosphorylation regulated by p38 is
involved in Bim expression and apoptosis in chronic myelogenous
leukemia cells induced by imatinib. Apoptosis. 19:1281–1292. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pommier Y, Leo E, Zhang H and Marchand C:
DNA topoisomerases and their poisoning by anticancer and
antibacterial drugs. Chem Biol. 17:421–433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cui X, Choi HK, Choi YS, Park SY, Sung GJ,
Lee YH, Lee J, Jun WJ, Kim K, Choi KC, et al: DNAJB1 destabilizes
PDCD5 to suppress p53-mediated apoptosis. Cancer Lett. 357:307–315.
2015. View Article : Google Scholar
|
|
21
|
Park JH, Lee SW, Yang SW, Yoo HM, Park JM,
Seong MW, Ka SH, Oh KH, Jeon YJ and Chung CH: Modification of DBC1
by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA
damage. Nat Commun. 5:54832014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okamoto S, Jiang Y, Kawamura K, Shingyoji
M, Tada Y, Sekine I, Takiguchi Y, Tatsumi K, Kobayashi H, Shimada
H, et al: Zoledronic acid induces apoptosis and S-phase arrest in
mesothelioma through inhibiting Rab family proteins and
topoisomerase II actions. Cell Death Dis. 5:e15172014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu J, Uematsu H, Tsuchida N and Ikeda MA:
Essential role of caspase-8 in p53/p73-dependent apoptosis induced
by etoposide in head and neck carcinoma cells. Mol Cancer.
10:952011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hande KR: Etoposide: Four decades of
development of a topoisomerase II inhibitor. Eur J Cancer.
34:1514–1521. 1998. View Article : Google Scholar
|
|
25
|
Zhang Y, Geng L, Talmon G and Wang J:
MicroRNA-520g confers drug resistance by regulating p21 expression
in colorectal cancer. J Biol Chem. 290:6215–6225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Adi Harel S, Bossel Ben-Moshe N, Aylon Y,
Bublik DR, Moskovits N, Toperoff G, Azaiza D, Biagoni F, Fuchs G,
Wilder S, et al: Reactivation of epigenetically silenced miR-512
and miR-373 sensitizes lung cancer cells to cisplatin and restricts
tumor growth. Cell Death Differ. 22:1328–1340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang CH, Pfeffer SR, Sims M, Yue J, Wang
Y, Linga VG, Paulus E, Davidoff AM and Pfeffer LM: The oncogenic
microRNA-21 inhibits the tumor suppressive activity of FBXO11 to
promote tumorigenesis. J Biol Chem. 290:6037–6046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen J, Shen BY, Deng XX, Zhan Q and Peng
CH: SKP1-CULLIN1-F-box (SCF)-mediated DRG2 degradation facilitated
chemotherapeutic drugs induced apoptosis in hepatocellular
carcinoma cells. Biochem Biophys Res Commun. 420:651–655. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song H, Kim SI, Ko MS, Kim HJ, Heo JC, Lee
HJ, Lee HS, Han IS, Kwack K and Park JW: Overexpression of DRG2
increases G2/M phase cells and decreases sensitivity to
nocodazole-induced apoptosis. J Biochem. 135:331–335. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ko MS, Lee UH, Kim SI, Kim HJ, Park JJ,
Cha SJ, Kim SB, Song H, Chung DK, Han IS, et al: Overexpression of
DRG2 suppresses the growth of Jurkat T cells but does not induce
apoptosis. Arch Biochem Biophys. 422:137–144. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qiu Y, Song B, Zhao G, Deng B, Makino T,
Tomita Y, Wang J, Luo W, Doki Y, Aozasa K, et al: Expression level
of Pre B cell leukemia homeobox 2 correlates with poor prognosis of
gastric adenocarcinoma and esophageal squamous cell carcinoma. Int
J Oncol. 36:651–663. 2010.PubMed/NCBI
|
